The inhibition effect and mechanism of SY0916 on pulmonary fibrosis

Abstract

SY0916 is a new platelet-activating factor receptor antagonist developed by our institute. In this study, the inhibitory effect of SY0916 on pulmonary fibrosis was investigated in epithelial–mesenchymal transition (EMT) induced by transforming growth factor beta 1 (TGF-β1) in vitro and a pulmonary fibrosis animal model induced by bleomycin (BLM). The results showed that SY0916 could inhibit the EMT of A549 cells induced with TGF-β1. In vivo, SY0916 administration significantly ameliorated the BLM-mediated histological changes, reduced main biochemical parameters related to pulmonary fibrosis such as hydroxyproline and glutathione, and also notably attenuated the expression of key pro-fibrotic mediator, TGF-β1. These findings demonstrated that SY0916 could possibly be developed as a promising candidate for the treatment of pulmonary fibrosis.

Keywords::

• pulmonary fibrosis
• epithelial–mesenchymal transition
• platelet-activating factor receptor antagonist

Acknowledgments

This work was financially supported by the National High Technique Project of China (863 Project) (No. 2002AA233081), the National Natural Science Foundation of China (No. 81001443), and the Beijing Science and Technique Project (No. H020220060190).